When should surgery be used to supplement systemic therapy in metastatic renal cell cancer?
作者信息
Hardman Morgan, Gabriel Emmanuel
机构信息
Mayo Clinic Alix School of Medicine, Mayo Clinic, Jacksonville, FL, USA.
Division of Surgical Oncology, Department of Surgery, Mayo Clinic, Jacksonville, FL, USA.
出版信息
J Thorac Dis. 2023 Jun 30;15(6):2896-2898. doi: 10.21037/jtd-23-457. Epub 2023 Jun 5.
Abstract
摘要
相似文献
1
When should surgery be used to supplement systemic therapy in metastatic renal cell cancer?在转移性肾细胞癌中，何时应采用手术来辅助全身治疗？
J Thorac Dis. 2023 Jun 30;15(6):2896-2898. doi: 10.21037/jtd-23-457. Epub 2023 Jun 5.
2
A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma.一项系统综述：全身治疗在肾细胞癌脑转移治疗和预防中的作用
J Oncol Pharm Pract. 2020 Jun;26(4):972-981. doi: 10.1177/1078155220905648. Epub 2020 Feb 25.
3
Clinical utility of head computed tomography scan during systemic therapy for metastatic renal cell carcinoma.头部计算机断层扫描在转移性肾细胞癌全身治疗中的临床应用价值
Int J Urol. 2021 Apr;28(4):450-456. doi: 10.1111/iju.14490. Epub 2021 Feb 1.
4
Surgical treatment of adrenal metastasis from renal cell carcinoma: a single-centre experience of 45 patients.肾细胞癌肾上腺转移的外科治疗：45例患者的单中心经验
BJU Int. 2006 Mar;97(3):505-8. doi: 10.1111/j.1464-410X.2006.05934.x.
5
Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?舒尼替尼治疗转移性肾细胞癌时持续的全身反应与卵巢转移进展平行：这是癌症的抗血管生成增强作用吗？
Urol Ann. 2015 Jul-Sep;7(3):387-90. doi: 10.4103/0974-7796.153669.
6
Neoadjuvant (presurgical) therapy for renal cell carcinoma: a new treatment paradigm for locally advanced and metastatic disease.肾细胞癌的新辅助（术前）治疗：局部晚期和转移性疾病的新治疗模式。
Cancer. 2009 May 15;115(10 Suppl):2355-60. doi: 10.1002/cncr.24240.
7
[Management of metastatic renal cell carcinomass].
Prog Urol. 2018 Nov;28(14):777-782. doi: 10.1016/j.purol.2018.07.280. Epub 2018 Aug 31.
8
Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy.伴有下腔静脉侵犯的转移性肾细胞癌：根治性肾切除术、腔静脉血栓切除术及术后免疫治疗联合治疗后的长期生存情况
J Urol. 1999 Jul;162(1):46-50. doi: 10.1097/00005392-199907000-00012.
9
New systemic treatment options for metastatic renal-cell carcinoma in the era of targeted therapies.靶向治疗时代转移性肾细胞癌的新型全身治疗选择
Asia Pac J Clin Oncol. 2010 Mar;6(1):5-18. doi: 10.1111/j.1743-7563.2010.01277.x.
10
Current Management Options in Metastatic Renal Cell Cancer.转移性肾细胞癌的当前管理选择
Oncol Rev. 2017 Jun 14;11(2):339. doi: 10.4081/oncol.2017.339.
本文引用的文献
1
Surgery for thoracic oligoprogression in metastatic renal cell cancer in the era of new systemic therapies.新型全身治疗时代转移性肾细胞癌胸段寡进展的手术治疗
J Thorac Dis. 2023 Mar 31;15(3):1133-1141. doi: 10.21037/jtd-22-1120. Epub 2023 Mar 20.
2
Pathological Complete Response of Metastatic Clear Cell Renal Carcinoma with Pembrolizumab and Axitinib: A Case Report and Review of Literature.帕博利珠单抗联合阿昔替尼治疗转移性透明细胞肾细胞癌的病理完全缓解：1例病例报告及文献复习
Case Rep Oncol. 2023 Feb 2;16(1):30-35. doi: 10.1159/000529124. eCollection 2023 Jan-Dec.
3
Perirenal Fat Thickness Significantly Associated with Prognosis of Metastatic Renal Cell Cancer Patients Receiving Anti-VEGF Therapy.肾周脂肪厚度与接受抗血管内皮生长因子治疗的转移性肾细胞癌患者的预后显著相关。
Nutrients. 2022 Aug 18;14(16):3388. doi: 10.3390/nu14163388.
4
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?一线免疫检查点抑制剂联合治疗转移性肾细胞癌：我们去向何方，我们从何处来？
Drugs. 2022 Mar;82(4):439-453. doi: 10.1007/s40265-022-01683-6. Epub 2022 Feb 17.
5
Metastatic Clear Cell Renal Cell Carcinoma: The Great Pretender and the Great Dilemma.转移性透明细胞肾细胞癌：伪装高手与巨大困境
World J Oncol. 2021 Oct;12(5):178-182. doi: 10.14740/wjon1406. Epub 2021 Oct 21.
6
Treatment Strategies for Oligometastatic Breast Cancer.寡转移乳腺癌的治疗策略。
Curr Treat Options Oncol. 2021 Aug 23;22(10):94. doi: 10.1007/s11864-021-00889-2.
7
Metastasectomy for Stage IVA Colon Cancer: Does the Type of Treating Institution Make a Difference?IVA 期结肠癌转移切除术：治疗机构的类型有影响吗？
Am Surg. 2022 Aug;88(8):1976-1982. doi: 10.1177/00031348211023389. Epub 2021 Jun 2.
8
Renal cell carcinoma (RCC): fatter is better? A review on the role of obesity in RCC.肾细胞癌（RCC）：胖点更好？肥胖在肾细胞癌中作用的综述
Endocr Relat Cancer. 2021 Jun 2;28(7):R207-R216. doi: 10.1530/ERC-20-0457.
9
Predicting Response to Immunotherapy in Metastatic Renal Cell Carcinoma.预测转移性肾细胞癌对免疫疗法的反应
Cancers (Basel). 2020 Sep 18;12(9):2662. doi: 10.3390/cancers12092662.
10
The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR receptor.贝伐珠单抗/阿瓦斯汀与厄洛替尼/特罗凯联合治疗转移性肾细胞癌：表皮生长因子受体同义突变的作用。
Theranostics. 2020 Jan 1;10(3):1107-1121. doi: 10.7150/thno.38346. eCollection 2020.
Zotero 插件